■恶性胸腔积液(MPE)是一种情况,这可以在15%的被诊断患有癌症的患者中看到。因为总生存期短,确定适当的治疗方法很重要。除了缓解由于MPE引起的继发性症状外,还应该决定在哪些情况下应遵循更积极的治疗。该研究的目的是评估LENT和临床PROMISE评分在预测MPE患者生存中的表现。
■年龄,性别,吸烟史,东部肿瘤协作组(ECOG)评分,癌症类型,化疗/放疗史,实验室值,记录胸水乳酸脱氢酶。计算LENT和PROMISE评分并确定风险类别。在后续行动中,对患者进行常规的血液检查和断层扫描对照.总生存期计算为从MPE诊断之日起至死亡或至2019年12月31日。
■共纳入169例患者。中位年龄为65(26-86)。在单变量分析中,不良绩效评分的死亡风险显着增加,如果LENT风险组从低到中/高风险组或PROMISEA类发展到B类,A到C或A到D在多变量分析中,1、3、6和12个月的死亡风险在不良表现评分中显著增加,在承诺类别B中,C,和D.在高LENT风险组中,仅12个月的生存时间显示死亡风险增加.
■我们的数据显示表现不佳(ECOG3-4),B类承诺,C,和D显着增加死亡风险,LENT评分不足以预测生存。
UNASSIGNED: Malignant pleural effusion (MPE) is a condition, that can be seen in 15% of patients diagnosed with cancer. Because of the short overall survival, it is important to identify the appropriate treatment. In addition to the palliation of secondary symptoms due to MPE, it should also be decided in which cases a more aggressive treatment is to be followed. The purpose of the study was to evaluate the performance of LENT and clinical
PROMISE scores in predicting survival in patients with MPE.
UNASSIGNED: Age, sex, smoking history, Eastern Cooperative Oncology Group (ECOG) score, cancer type, history of chemotherapy/radiotherapy, laboratory values, and pleural fluid lactate dehydrogenase were recorded. The LENT and the
PROMISE scores were calculated and risk categories were determined. During the follow-up, blood tests and tomography controls were performed on the patients as routine. The overall survival was calculated as the period from the date of diagnosis of MPE to death or until December 31, 2019.
UNASSIGNED: A total of 169 patients were included. The median age was 65 (26-86). In the single-variable analysis, there was a significant increase in mortality risk in the poor performance score and if the LENT risk group progressed from the low-to medium-/high-risk group or
PROMISE categories A to B, A to C or A to D. In multivariate analysis, mortality risk in 1, 3, 6, and 12 months increased significantly in poor performance score, in
PROMISE category B, C, and D. In high LENT risk-group, an increased mortality risk was shown in only 12 months of survival.
UNASSIGNED: Our data show that poor performance score (ECOG 3-4),
PROMISE category B, C, and D significantly increase mortality risk and the LENT score is inadequate in predicting survival.